MOAB VX15/2503 Uses, Dosage, Side Effects and more
MOAB VX15/2503 is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
| Trade Name | MOAB VX15/2503 |
| Generic | Pepinemab |
| Pepinemab Other Names | MOAB VX15/2503, Pepinemab, VX15/2503 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
